Variants in the GPR146 Gene Are Associated With a Favorable Cardiometabolic Risk Profile - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Arteriosclerosis, Thrombosis, and Vascular Biology Year : 2022

Variants in the GPR146 Gene Are Associated With a Favorable Cardiometabolic Risk Profile


BACKGROUND: In mice, GPR146 (G-protein-coupled receptor 146) deficiency reduces plasma lipids and protects against atherosclerosis. Whether these findings translate to humans is unknown. METHODS: Common and rare genetic variants in the GPR146 gene locus were used as research instruments in the UK-Biobank. The Lifelines, and The Copenhagen-City Heart Study, and a cohort of individuals with familial hypobetalipoproteinemia were used to find and study rare GPR146 variants. RESULTS: In the UK-Biobank, carriers of the common rs2362529-C allele present with lower low-density lipoprotein cholesterol, apo (apolipoprotein) B, high-density lipoprotein cholesterol, apoAI, CRP (C-reactive protein), and plasma liver enzymes compared with noncarriers. Carriers of the common rs1997243-G allele, associated with higher GPR146 expression, present with the exact opposite phenotype. The associations with plasma lipids of the above alleles are allele dose-dependent. Heterozygote carriers of a rare coding variant (p.Pro62Leu; n=2615), predicted to be damaging, show a stronger reductions in the above parameters compared with carriers of the common rs2362529-C allele. The p.Pro62Leu variant is furthermore shown to segregate with low low-density lipoprotein cholesterol in a family with familial hypobetalipoproteinemia. Compared with controls, carriers of the common rs2362529-C allele show a marginally reduced risk of coronary artery disease (P=0.03) concomitant with a small effect size on low-density lipoprotein cholesterol (average decrease of 2.24 mg/dL in homozygotes) of this variant. Finally, mendelian randomization analyses suggest a causal relationship between GPR146 gene expression and plasma lipid and liver enzyme levels. CONCLUSIONS: This study shows that carriers of new genetic GPR146 variants have a beneficial cardiometabolic risk profile, but it remains to be shown whether genetic or pharmaceutical inhibition of GPR146 protects against atherosclerosis in humans.
Fichier principal
Vignette du fichier
ATVBAHA.122.317514.pdf (1.07 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

inserm-03833180 , version 1 (28-10-2022)



A. Rimbert, M. W. Yeung, N. Dalila, C. H. L. Thio, H. Yu, et al.. Variants in the GPR146 Gene Are Associated With a Favorable Cardiometabolic Risk Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42 (10), pp.1262-1271. ⟨10.1161/atvbaha.122.317514⟩. ⟨inserm-03833180⟩
39 View
34 Download



Gmail Mastodon Facebook X LinkedIn More